Idiopathic Pulmonary Fibrosis

Race-Specific Reference Values Impede Access to Care for Black and Hispanic Patients with Pulmonary Fibrosis

An analysis of data from the Pulmonary Fibrosis Foundation Patient Registry to evaluate how using race-specific and race-neutral approaches to measuring pulmonary function can impact access to care for patients with pulmonary fibrosis from different race/ethnic backgrounds.

Independent content

European Respiratory Society (ERS) 2023: In-depth report

This in-depth report provides an overview of the latest advances in the diagnosis, treatment and management of chronic obstructive pulmonary disease and interstitial lung disease presented at ERS 2023.

Autoantibody Positivity in Idiopathic Pulmonary Fibrosis: Outcomes From the Pulmonary Fibrosis Foundation Patient Registry

This poster describes the baseline characteristics and clinical outcomes in patients with IPF from the Pulmonary Fibrosis Foundation Patient Registry (PFF-PR), stratified by baseline AAb status.

Factors Associated With Persistence With Antifi brotic Therapy in Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Pulmonary Fibrosis Foundation Patient Registry

PFF – This poster reports an analysis that aimed to investigate the demographic and clinical characteristics associated with antifibrotic therapy persistence among patients with IPF from the Pulmonary Fibrosis Foundation Patient Registry.

External Validation and Longitudinal Application of a Multidimensional Index to Individualize Survival Prediction in Idiopathic Pulmonary Fibrosis

DO-GAP - This poster reports an analysis that aimed to externally validate the DO-GAP index using clinical trial data from the CAPACITY studies.

Post-hoc analysis of clinical characteristics and outcomes in patients with idiopathic pulmonary fibrosis (IPF) by pulmonary vascular phenotype from CAPACITY

This post-hoc analysis aimed to determine if the mPAP calculator can be used to identify patients with less physiologically impaired IPF at risk of worse outcomes due to PH by comparing data from placebo-treated patients with probable PH vs those with unlikely PH from CAPACITY (NCT00287729; NCT00287716).

External site

Idiopathic Pulmonary Fibrosis

Ask a question or share feedback